Biogen Awaits Midyear BIIB080 Tau Data, Phase III Lupus Readouts
Biogen’s Phase 1b BIIB080 trial showed tau reductions and will deliver proof-of-concept data midyear to assess cognitive benefits. It also awaits two Phase III LITIFILIMAB SLE readouts this year, while high-dose SPINRAZA won approvals in US, Japan and Europe, and notes blood biomarkers could drive LEQEMBI maintenance adoption.
1. BIIB080 Tau Reduction Program
Priya Singhal highlighted that BIIB080, an antisense oligonucleotide targeting tau, achieved encouraging tau reductions in Phase 1b and will enter a proof-of-concept study with midyear data to evaluate cognitive benefits across dosing regimens.
2. LITIFILIMAB Phase III SLE Trials
Biogen expects two Phase III LITIFILIMAB trials in systemic lupus erythematosus to read out this year and will consider a combined data filing if one trial is positive and the other shows positive trends.
3. High-Dose SPINRAZA Approval and Uptake
The high-dose formulation of SPINRAZA received approvals in the US, Japan and Europe, with initial patient uptake and physician feedback described as positive.
4. Biomarkers and SYFOVRE Competitive Dynamics
Biogen noted that CMS now allows blood-based biomarkers for Alzheimer’s confirmation, which may increase LEQEMBI maintenance adoption, and reiterated SYFOVRE’s lesion-growth reduction data supports its position against visual-acuity-focused competitors.